作者: Julien J. Feghaly , Arshag D. Mooradian
DOI: 10.1007/S40265-020-01265-4
关键词: Reverse cholesterol transport 、 Clinical trial 、 Pharmacotherapy 、 Cholesterylester transfer protein 、 Medicine 、 Nicotinic agonist 、 Endocrinology 、 Randomized controlled trial 、 De novo synthesis 、 Internal medicine 、 Inverse correlation
摘要: Earlier epidemiological studies have shown an inverse correlation between high-density lipoprotein cholesterol (HDLc) and coronary heart disease (CHD). This observation along with the finding that reverse transport is mediated by HDL, supported hypothesis HDL molecule has a cardioprotective role. More recently, data suggest U-shaped curve correlating HDLc CHD. In addition, randomized clinical trials of drugs significantly increase plasma levels, such as nicotinic acid ester transfer protein (CETP) inhibitors failed to show reduction in major adverse cardiovascular events. These observations challenge It possible quality function optimal only when de novo synthesis apo A-I occurs. Inhibition turnover currently available agents yields molecules are ineffective transport. To test this hypothesis, newer therapeutic production should be tested trials.